MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $28.61 | Prev. Close $28.68 | Circuit Range N/A |
Day Range $27.81 - $28.83 | Year Range $4.81 - $44.77 | Volume 11,883 |
Average Traded $28.40 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
17-Mar-26 | $28.79 | $29.73 | -0.13% |
16-Mar-26 | $29.66 | $29.77 | +6.09% |
13-Mar-26 | $28.37 | $28.06 | +0.39% |
12-Mar-26 | $28.11 | $27.95 | -3.49% |
11-Mar-26 | $28.14 | $28.96 | -0.07% |
10-Mar-26 | $28.42 | $28.98 | +3.91% |
09-Mar-26 | $30.26 | $27.89 | -8.80% |